<DOC>
	<DOCNO>NCT01449578</DOCNO>
	<brief_summary>This Phase 1 study explore safety , tolerability , pharmacokinetics single dos range 300 600 mg multiple daily dos range 225 mg 300 mg BID dexpramipexole healthy volunteer .</brief_summary>
	<brief_title>Dexpramipexole SAD/MAD Study</brief_title>
	<detailed_description>Preclinical clinical data date support exploration dose dexpramipexole high 150 mg twice daily effectiveness slow progression ALS . Exploration dose dexpramipexole high 150 mg twice daily justified preclinical clinical data suggest high dos could potentially effective slow progression ALS dose dexpramipexole currently explore Phase 3 study ( 150 mg twice daily ) . This Phase 1 , single-center , blind , randomize , placebo control , ascending-dose study consist 2 part ; Part A ( single-ascending dose [ SAD ] ) Part B ( multiple ascend dose [ MAD ] ) . The study explore safety , tolerability , pharmacokinetics single dos range 300 600 mg multiple daily dos range 225 mg 300 mg BID dexpramipexole healthy volunteer .</detailed_description>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Must give write informed consent . Adult males/females age 18 55 year inclusive 19 30 kg/m2 body mass index ( BMI ) , inclusive screening . Subjects healthy determine prestudy medical history , physical examination 12lead ECG . Subjects childbearing potential must practice effective contraception study willing able continue contraception 1 month ( female ) 3 month ( male ) last dose study treatment . Normal systemic blood pressure define systolic blood pressure 90 140 mmHg diastolic blood pressure 50 90 mmHg . History cardiovascular disease ( e.g. , hypertension , arrhythmia , heart failure , Long QT Syndrome , conditions/diseases cause prolongation QT/QTc interval ) . A prolongation QT/QTc interval ( e.g. , repeated demonstration QT/QTc interval &gt; 450 m study treatment administration ) screening , admission predose Day 1 . Any clinically important abnormality rest ECG may interfere interpretation QTc interval change screen , admission predose Day 1 . Prior exposure dexpramipexole . Treatment pramipexole dopamine agonist within 1 year . Treatment another investigational drug approve therapy investigational use within 30 day , 5 halflives ( whichever longer ) , follow drug , biologic , device study . Currently active infection serious infection ( e.g. , pneumonia , septicemia ) within 2 month prior Day 2 determine Investigator . Female subject pregnant , currently breastfeed , attempt conceive study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>